Cargando…
Development of an advanced cell therapy product indicated for the treatment of gonarthrosis
Autores principales: | Vives, Joaquim, Blanco, Margarita, Caminal, Marta, Coca, Maria I, Codinach, Margarita, Coll, Ruth, Doral, Manuel, Lloret, Mireia, Oliver-Vila, Irene, Ortega, Isabel, Reales, Laura, Requena-Montero, Míriam, Rodríguez, Luciano, Torrents, Sílvia, García, Joan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685328/ http://dx.doi.org/10.1186/1753-6561-9-S9-O9 |
Ejemplares similares
-
Optimized reagents for immunopotency assays on mesenchymal stromal cells for clinical use
por: Torrents, Sílvia, et al.
Publicado: (2023) -
Compliance with Good Manufacturing Practice in the Assessment of Immunomodulation Potential of Clinical Grade Multipotent Mesenchymal Stromal Cells Derived from Wharton’s Jelly
por: Grau-Vorster, Marta, et al.
Publicado: (2019) -
Treatment of Advanced Stage Gonarthrosis With Prolotherapy: Case Report
por: Solmaz, Ilker, et al.
Publicado: (2013) -
CORRELATION BETWEEN AHLBÄCK CLASSIFICATION AND GONARTHROSIS RISK FACTORS
por: Borges, Paulo Alvim, et al.
Publicado: (2018) -
Serum progranulin to TNF-α ratio in patients with gonarthrosis
por: Yıldız, Kadri, et al.
Publicado: (2021)